Overview

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

Status:
Recruiting

Trial end date:
2026-03-31

Target enrollment:

Participant gender:

Summary

This study will evaluate the efficacy and safety of multiple biomarker-driven treatments in patients with persistent or recurrent rare epithelial ovarian, fallopian tube, or primary peritoneal tumors. Enrollment will take place in two phases: a preliminary phase followed by a potential expansion phase.

Phase:

Phase 2

Details

Lead Sponsor:

Hoffmann-La Roche

Collaborators:

European Network of Gynaecological Oncological Trial Groups (ENGOT)
GOG Foundation

Treatments:

Ado-Trastuzumab Emtansine
Atezolizumab
Bevacizumab
Maytansine
Paclitaxel
Trastuzumab